Top story · October 28, 2026
The Jersey Shore star reports four months of sobriety after treatment in Mexico.
Ronnie Ortiz-Magro claims ibogaine treatment in Mexico helped him achieve sobriety, despite its controversial status.
Read the storyOctober 28, 2026
A personal account highlights the risks of unregulated ibogaine use.
October 28, 2026
Psychedelics like MDMA and psilocybin gain traction amid regulatory challenges.
October 28, 2026
The center reaffirms its mission with refined ibogaine protocols.
October 28, 2026
The 'Jersey Shore' star shares his journey to recovery using ibogaine treatment.
October 26, 2026
At 80, Giordano champions ibogaine for addiction recovery, leveraging personal history.
October 26, 2026
Stakeholders express varied opinions on FDA's recent psychedelics docket, highlighting diverse perspectives.
October 26, 2026
Ibogaine's legal complexities offer insights for regulatory frameworks.
October 26, 2026
Universal Ibogaine's market performance and developments tracked.
October 26, 2026
Proposal aims to address PTSD in veterans using psychedelic treatments.
October 23, 2026
TradingView provides financial estimates for Universal Ibogaine Inc.
October 22, 2026
The group emphasizes cardiac risk management in ibogaine clinical trials.
October 22, 2026
Federal officials discuss the complexities of psychedelic access for veterans.
October 21, 2026
Psychedelics shift from counterculture to tech industry darling, reshaping capitalism.
October 21, 2026
Non-hallucinogenic psychiatric candidate shows promise in early trials.
October 21, 2026
Preclinical study explores ibogaine and citalopram combination for depression.
October 21, 2026
Matt Zorn discusses his transition from legal adversary to HHS official.
October 21, 2026
Psyence BioMed invests in PsyLabs following milestone achievements.
October 21, 2026
Investment completion coincides with key ibogaine research milestones.
October 20, 2026
Interest in ibogaine for addiction treatment raises conservation concerns in Gabon.
October 20, 2026
Executive order allocates $50 million for psychedelic drug development, including ibogaine.
October 19, 2026
Singer-songwriter Danny Malone's new album follows recovery from addiction with ibogaine therapy.
October 19, 2026
FDA's request for ibogaine trial input marks a step in psychedelic drug regulation.
October 18, 2026
Gabon bans iboga exports to safeguard cultural heritage amid rising global interest.
October 17, 2026
Fox News at Night discusses current events and issues on October 16.
October 17, 2026
Morningstar provides insights into the financial performance of Universal Ibogaine Inc.
October 16, 2026
Malone's new song marks a comeback after battling addiction and personal loss.
October 16, 2026
Dune: Part Three explores complex scientific ideas, including ibogaine's potential.
October 16, 2026
Ibogaine treatment offered to athletes with traumatic brain injuries.
October 16, 2026
Pharmaceutical giant Lilly shows interest in advancing ibogaine studies.
October 16, 2026
Psychedelic ibogaine could offer new hope for opioid addiction recovery.
October 15, 2026
New initiative to support athletes with traumatic brain injury using ibogaine.
October 14, 2026
FDA approves TELA Bio's first in-house developed resorbable mesh, expanding their product line.
October 14, 2026
New review highlights ibogaine's promise and dangers in addiction therapy.
October 13, 2026
Market Exclusive highlights recent developments in cannabis and psychedelics.
October 11, 2026
Ibogaine trials for opioid use disorder face scrutiny over safety.
October 10, 2026
Proceeds from the auction will support Americans for Ibogaine's efforts to mainstream ibogaine treatment.
October 10, 2026
Shawn Ryan's story underscores the dangers of seeking healing through psychedelics.
October 10, 2026
Gonzalez to enhance Jungian assessments and spearhead clinical research.
October 9, 2026
FDA's request for ibogaine trial proposals highlights cardiac risks and regulatory challenges.
October 9, 2026
Gabon aims to secure benefits from rising ibogaine demand
October 9, 2026
Potential trials could explore ibogaine's role in treating opioid addiction.
October 9, 2026
A year-long study suggests ibogaine may help veterans with PTSD, but more research is needed.
October 9, 2026
HHS plans to allow unapproved peptides, sparking FDA staff concerns.
October 9, 2026
Exploring safety and design in ibogaine trials for opioid use disorder.
October 9, 2026
Film offers rare insight into psychedelic therapy for trauma and addiction.
October 8, 2026
Years-long battle with substance use reportedly impacts Gerber's life.
October 8, 2026
Unverified claims of costly measures and shocking outcomes emerge.
October 8, 2026
Federal funds may replace private investment in Texas ibogaine research
October 8, 2026
Study finds significant symptom improvement in PTSD, depression after ibogaine treatment.
Newsletter
Occasional dispatches on research, policy, and treatment. No spam.